H-P CEO Asks for Five Years and 3 Dow Movers Demanding Attention
Chevron Corporation (NYSE:CVX): Current price $111.92
Chevron, the second-largest domestic oil company after Exxon Mobil Corporation in market value, anticipates fourth-quarter earnings that are “notably higher” than those of the third quarter, even as the residuals of the August fire at its California refinery lingered. Chevron benefited from a $1.4 billion asset exchange in Australia, and West Texas oil field purchases that boosted its oil and gas output. In addition, its bottom line was helped by a slight rebound in oil and natural gas prices midway through the quarter. In its third quarter, a gain of $600 million in revenues contributed to a profit of $5.25 billion.
General Electric Co. (NYSE:GE): Current price $21.22
Briggs & Stratton Corporation (NYSE:BGG) has made a multi-year agreement with GE Capital Retail Bank through which to supply private label retail financing programs for power equipment and standby generators. The latter provides financial solutions for manufacturers and dealers to assist them in growing their customer sales.
Hewlett-Packard Company (NYSE:HPQ): Current price $15.92
The present challenges for Hewlett-Packard are formidable as its customers are purchasing less of two of HP’s most important products — PCs and printers — while the firm has accumulated debt and spent billions on acquisitions that turned out to be unwise, according to Bloomberg Businessweek. Meanwhile, back on Wall Street, analysts want the company to be broken up. Since August of 2010, its share price has tumbled by 70 percent and it has lost about $68 billion in value. However, a number of its businesses are cash machines and the firm generates over $12 billion in operating income per year. Chief Executive Meg Whitman says that she will make difficult decisions in the future, but needs time to change things, perhaps five years.
Johnson & Johnson (NYSE:JNJ): Current price $72.50
J&J’s subsidiary Janssen-Cilag International said that the European Commission has okayed an extension to the license of the oral, once-daily medication Zytiga. The approved broader indication for the drug now includes its use, in combination with prednisone or prednisolone for treating metastatic castration-resistant prostate cancer, in adult men who are asymptomatic or mildly symptomatic following the failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
Investing Insights: Is United Technologies a Buy Now?